DentaQuest Partnership and 120 Industry Leaders Create New Framework For More Sustainable Oral Health System

Three Domain Framework is the future of dentistry

Boston, Oct. 26, 2020 (GLOBE NEWSWIRE) — Even as the COVID-19 pandemic exacerbates the nation’s broken oral health care system, it has created an opportunity for the industry to move toward a new, more sustainable model centered around the patient, primary care and prevention. The DentaQuest Partnership for Oral Health Advancement released a report today — based on the work of the Community Oral Health Transformation Initiative learning community — that establishes a primary care-like structure for oral health care delivery, facilitates value-based payment models and enables patients to invest in their own oral health.

120 of the industry’s most prominent organizations and leaders contributed to the development of the Three Domain Framework, which lays out a clear path for providers and practices to expand access to care, improve health outcomes and reduce the cost burdens associated with poor quality of life due to oral disease.

The framework gives patients and dental and medical providers the freedom to collaborate on treatment plans that work best for a given situation within the context of overall health. And it emphasizes patient and provider safety while addressing critical gaps in both patients’ access to care and providers’ financial viability.  

“Oral health is directly linked to overall health, but our current system doesn’t reflect that reality,” said Dr. Sean Boynes, vice president of health improvement for the DentaQuest Partnership for Oral Health Advancement. “And COVID-19 has shined a bright spotlight on this flaw. The Three Domain Framework outlines a new approach for oral health — one that focuses on prevention and healthy outcomes, facilitates value-based payment models, and will help address deep disparities in care and access. We are grateful to the many contributors who are working together to put our oral health system on a new and better path. This is the future of dentistry.”

The three domains can be adopted in any order, meaning the care team can determine where to begin. Providers can safely begin shifting their models of dentistry by starting in a domain that supports their unique needs and those of their patients. 

Domain One: Advancements in Teledentistry

The pandemic has increased interest in and utilization of teledentistry, but widespread adoption requires defining new treatment codes and rethinking the flow of care for a variety of dental visits. Domain One focuses on the identification, development and adoption of telehealth strategies and builds an accessible evidence-based virtual delivery approach specific to oral health that can enhance disease prevention and whole-person health.

Domain Two: Prioritization of Minimally Invasive Care

The pandemic also sparked interest in Minimally Invasive Care (MIC), as providers sought treatment methods, like sealants and silver diamine fluoride, that limit aerosols and the spread of COVID-19. MIC can reverse or slow early disease stages using a program of anticipatory guidance and collaborative decision-making with patients. Domain Two prioritizes the use of MIC for oral health management and maintenance.

Domain Three: Integration and Personalization of Oral Care Delivery

Domain Three

Read more

Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients

  • Roche and Atea partner to jointly develop AT-527, an orally administered direct-acting antiviral (DAA) currently in Phase 2 clinical trials

  • AT-527 has the potential to be the first novel oral antiviral to treat COVID-19 patients outside the hospital setting as well as in the hospital and may also be used in post-exposure prophylactic settings

  • Oral, small-molecule DAAs for COVID-19 patients allow for large-scale manufacturing and facilitate broad patient access

  • If approved, Atea will distribute AT-527 in the United States and Roche will be responsible for global manufacturing and distribution outside the United States

Basel, 22 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Atea Pharmaceuticals, Inc. announced today that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute AT-527, Atea’s investigational oral direct-acting antiviral, to people around the globe. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral replication, and is currently being studied in a Phase 2 clinical trial for hospitalised patients with moderate COVID-19. A Phase 3 clinical trial, expected to start in Q1 2021, will explore the potential use in patients outside of the hospital setting. In addition, AT-527 may be developed for post-exposure prophylactic settings.

AT-527, while being a potential oral treatment option for hospitalised patients, also holds the potential to be the first oral treatment option for COVID-19 patients that are not hospitalised.  Additionally, the manufacturing process of small-molecule DAAs allows the ability to produce large quantities of a much needed treatment. If successful, AT-527 could help treat patients early, reduce the progression of the infection, and contribute to decreasing the overall burden on health systems.

The collaboration aims to accelerate the clinical development and manufacturing of AT-527, to investigate its safety and efficacy, and to provide this potential treatment option to patients around the world as quickly as possible. If AT-527 proves safe and effective in clinical trials and regulatory approvals are granted, Atea will be responsible for distributing this treatment option in the U.S, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the United States.

“The ongoing complexities of COVID-19 require multiple lines of defence. By joining forces with Atea, we hope to offer an additional treatment option for hospitalised and non-hospitalised COVID-19 patients, and to ease the burden on hospitals during a global pandemic.” said Bill Anderson, Chief Executive Officer of Roche Pharmaceuticals. “In jointly developing and manufacturing AT-527 at scale, we seek to make this treatment option available to as many people around the world as we possibly can.”

“Roche shares our passion for delivering innovative new medicines to address great unmet medical needs. The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea Pharmaceuticals. “AT-527 is expected to be ideally suited to combat COVID-19 as it inhibits viral replication by interfering with viral RNA polymerase, a key component in the

Read more

AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma

Paris, October 20, 2020, 9.15pm

AB Science announces positive top-line Phase 3 results
 for oral masitinib in severe asthma

This is the second Phase 3 study to demonstrate efficacy for masitinib in severe asthma

AB Science SA (Euronext – FR0010557264 – AB) today announced that the Phase 3 study (AB14001) evaluating oral masitinib in severe asthma uncontrolled by high-dose inhaled corticosteroids (ICS) and with eosinophil level >150 cells/μL met its primary endpoint.

The pre-specified primary analysis was rate of severe asthma exacerbations, with masitinib demonstrating a statistically significant 29% reduction in severe exacerbations relative to placebo (p=0.022). The frequency of severe asthma exacerbations was 0.43 in the masitinib arm, versus 0.62 in the placebo arm. Duration of exposure was well-balanced between the treatment-arms (16 months in the masitinib arm and 17 months in the placebo arm). Sensitivity analysis based on the rate of moderate and severe asthma exacerbations was consistent with the primary analysis and detected a statistically significant 31% reduction in exacerbations (p=0.005) between masitinib and placebo. The frequency of moderate and severe asthma exacerbations was 0.55 in the masitinib arm, versus 0.80 in the placebo arm.

This is the second time that masitinib has demonstrated efficacy in reducing severe asthma exacerbations in patients with severe asthma. The treatment effect observed in study AB14001 is comparable with the effect previously reported for study AB07015. In that first phase 3 study, which evaluated masitinib in severe asthma uncontrolled by oral corticosteroids (OCS), masitinib significantly (p=0.010) reduced the rate of severe asthma exacerbations by 35% as compared with placebo. The frequency of severe asthma exacerbations in study AB07015 was 0.34 in the masitinib arm, versus 0.45 in the placebo arm. Duration of exposure was also well-balanced between the treatment arms (13 months in both treatment arms).
Safety was consistent with the known tolerability profile for masitinib.

Detailed results will be presented at an upcoming medical meeting.

The study AB14001 enrolled patients with blood eosinophil level >150 cells/μL, which differs from the population usually addressed by biological treatments, targeting patients with high eosinophils (>300 cells/μL or above) defined as Th2-high eosinophilic asthma.

Masitinib is a first in class drug in severe asthma, distinct from biological treatments targeting type-2 high eosinophilic phenotypes of asthma. Masitinib has a dual mechanism of action, targeting mast cells and PDGFR signaling that are both involved in airway remodeling associated with severe asthma. It has also been shown that increased mast cell activity is associated with both eosinophilic (Th2-high) and non-eosinophilic (Th2-low) asthma phenotypes. Furthermore, masitinib is orally administered, whereas biologics are sub-cutaneous, which is an advantage because oral administration is less of a burden for patients and facilitates compliance for long-term use.

There is still a need for effective therapy of patients with severe asthma. Biologics are established in first line treatment in severe asthma patients with blood eosinophil levels of ≥300 cells/µL. However, these therapies have limited efficacy in reducing severe asthma exacerbations for severe asthmatics with blood eosinophil levels of <300 cells/µL. In

Read more

Porter dentist offers free oral cancer screenings for firefighters

As a thank you to local first responders, Porter Family Dentistry is offering free oral cancer screenings to firefighters in Montgomery County for the next several weeks.

The screenings will be held on Fridays when the office is usually closed so that firefighters don’t have to wait.

In 2016, the National Institute for Occupational Safety and Health published a multi-year study of cancer rates in firefighters, and the findings showed that firefighters had a higher number of cancer diagnoses and cancer-related deaths than the general U.S. population. Among the cancers found in the sample of nearly 30,000 firefighters, those most often found were digestive, oral, respiratory, and urinary cancers.

In recent months, firefighters across the country have been traveling to areas, like California, that their help is needed. Dr. Mustafa Yamani of Porter Family Dentistry went to school in California and has fond memories of the nature and beauty of the state.

“It’s such a beautiful place, it’s really sad reading all of the stuff in the news that’s going on there,” Yamani said. “From all around the country they (the firefighters) come together and they provide this service. It’s just amazing what they’re doing and I really appreciate that. I just want to do something for them.”

The generous act of the firefighters inspired him to give back, and since oral cancer screenings are a service his office already offers he decided to give them to firefighters for free.

While this is the first year that the dental office has offered free screenings, Yamani and his wife Sabrina, who is the office manager, plan on making it an annual thing. The trials of 2020 also helped them decide to give back.

“Things seem to be going from bad to worse, to even worse, and it just doesn’t seem to be stopping for our first responders,” Sabrina said. “They’re just being hit with things one after the other.”

Sabrina started by reaching out to fire departments in the east past of Montgomery County to let them know about the opportunity and the response was immediate and positive. Already, the dental office has screenings set up with local firefighters.

Because firefighters are at a higher risk of developing cancer, many departments take an aggressive approach to screenings and check-ups. Early detection is vital. Such is the approach of the East Montgomery County Fire Department where firefighters undergo a National Fire Protection Agency physicals annually.

“It’s huge to us,” Eran Denzler, captain and PIO with the department, said of being able to get the oral screenings for free. “It’s a great show of appreciation for what we do and the risks that we take. Every day we go and put our lives on the line for the community, and for them to give back and worry about our safety is something we’re not used to but it’s much appreciated.”

The department averages around one to two structure fires a week,

Read more